Targeted BEACOPP Variants in Patients With Newly Diagnosed Advanced Classical Hodgkin Lymphoma

• Status: Completed
• Trial end date: 2017-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The Purpose of this trial is:

• to determine complete response rate (CRR) after six cycles of chemotherapy

• to determine complete remission rate (CR/CRr) as final treatment outcome after completion of treatment

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Cologne
• Treatments: Antibodies, Monoclonal; BB 1101; Brentuximab Vedotin; Cyclophosphamide; Dacarbazine; Dexamethasone; Dexamethasone 21-phosphate; Dexamethasone acetate; Doxorubicin; Etoposide; Prednisone; Procarbazine

Criteria

Inclusion Criteria:

• Histologically proven classical Hodgkin lymphoma

• First diagnosis, no previous treatment, age: 18-60 years

• Stage IIB with large mediastinal mass and/or extranodal lesions, stage III or IV disease

Exclusion Criteria:

• Composite lymphoma or nodular lymphocyte- predominant Hodgkin lymphoma (NLPHL)

• Previous malignancy

• Prior chemotherapy or radiation